|
3.3 Prévention - Vaccins
|
|
|
Short Answers to Hard Questions About HPV [NY Times]
|
|
|
|
|
|
Recent
data from a survey by the Centers for Disease Control and Prevention
found that in the decade since the vaccine was introduced, cases of HPV
infection in teenage girls had decreased by almost two-thirds.
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
Advancing the Potential and Promise of Total-Body PET Imaging [NCI]
|
|
|
|
|
|
This
new PET scanner, whose development has received substantial financial
support from NCI and NIBIB, is designed to rapidly provide detailed
information about tissues throughout the entire body while using a much
smaller amount of radioactivity than a standard PET scan.
|
|
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
FDA Offers its Views on Medical Device Trials [RAPS]
|
|
|
|
|
|
Unlike
for pharmaceuticals, which generally see double-blind, randomized,
Phase 3 trials assessing outcomes prior to approval, "practical
limitations related to the device or disease condition require
alternative approaches" for many devices, CDRH’s Owen Faris and Jeffrey
Shuren write.
|
|
|
|
|
|
|
4.11 Dép., diag. & prono. - Ovaire
|
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
Angst in the IO Combo field – part 2 (lessons from #AACR17) [SugarCone Biotech]
|
|
|
|
|
|
At
AACR, Dan Chen (from Genentech, a Roche company) laid out the case for
using not 1, not 2, not 3, not 4, not 5 … but up to 11 different
therapeutics to successfully treat a given tumor – he exaggerated to
make the point that none of the current immune checkpoint inhibitors
(ICIs) should be expected to work in synergy with anti-PD-1 therapy, a
priori.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
Medivir posts lymphoma data, guns to get into phase 3 [FierceBiotech]
|
|
|
|
|
|
Investigators
enrolled 60 patients with the slow-growing mycosis fungoides form of
CTCL, a type of non-Hodgkin lymphoma that initially manifests as
eczemalike skin patches. Medivir randomized the participants to receive
one of three regimens of topical HDAC inhibitor remetinostat.
|
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
FDA unease about faster drug approval [BMJ]
|
|
|
|
|
|
The
report is a surprisingly thorough compilation of 22 specific case
studies of drugs, vaccines, and medical devices. In each case, the
product showed promising results in phase II studies but failed to shine
in phase III trials—and ultimately was not approved for the intended
indication
|
|
|
|
|
|
|
5.9 AACR
|
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.9 Controverses
|
|
|